The efficacy of chemotherapy and splenic irradiation in the management of chronic myelogenous leukaemia at Ibadan, Nigeria.
Chronic myelogenous leukaemia (CML) in Nigerians shows a male predominance over females as has been observed in other centres. Out of 25 patients treated between 1987 and 1990, 18 were male. The mean survival of CML patients on chemotherapy was 48.7 months with a median of 38 months, while the mean survival of patients who had chemotherapy plus splenic irradiation was 53.3 months with a median survival of 53 months. The difference between the two mean survival rates was non-significant. Splenic irradiation resulted in significant reduction in splenic size with total disappearance of gastrointestinal symptoms. The need for red cell and blood products transfusion diminished. Patients had a feeling of well being though short-lived. In a developing country, the added cost of irradiation must be weighted against the relatively brief improvement in well-being when deciding mode of management of the disease. Cause of death in all cases was septicaemia, complications of thrombocytopaenia and marrow failure.
Aken'Ova
Y A
YA
Department of Haematology, University College Hospital, Ibadan.
Campbell
O B
OB
D002066:Busulfan / Q000627:therapeutic use; D002423:Cause of Death; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003906:Developing Countries; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D009549:Nigeria; D013154:Spleen / Q000528:radiation effects; D013163:Splenomegaly / Q000532:radiotherapy; D015996:Survival Rate
D003520:Cyclophosphamide; D002066:Busulfan